Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

Paolo Di Bartolo, Francesca Pellicano, Antonio Scaramuzza, Cipriana Sardu, Tino Casetti, Emanuele Bosi, Valerio Miselli, Sara Brandolini, Tiziano Fabbri, Piero Meandri, Francesco Cannatà

Research output: Contribution to journalArticle

Abstract

Background: Persistent glucose variability is a frequent condition in type 1 diabetes. Continuous subcutaneous insulin infusion (CSII) is a rational option to overcome this clinical issue; however, no comparative studies have been reported for aspart and lispro insulin when used in CSII. This study compare the effects of aspart and lispro delivered by CSII on glycemic stability as measured using a continuous glucose monitoring system. Methods: This single-center, randomized, controlled, 3-day crossover trial included 17 patients with type 1 diabetes. Patients were randomized to receive insulin aspart or insulin lispro. The next day, they received a standard meal at breakfast and lunch and a bolus of insulin aspart or lispro based on insulin:carbohydrate ratio. Patients were monitored for 8 h, after which they received a crossover treatment with insulin aspart or insulin lispro followed by the same procedure as previously. Results: Postprandial blood glucose was more stable with insulin aspart than insulin lispro (absolute Δglucose 7.04 ± 3.16 vs. 9.04 ± 4.2, P <0.0019). Daily blood glucose variability profiles (coefficient of variation and mean amplitude of glucose excursion) and frequency of hypoglycemic episodes (area under the curve

Original languageEnglish
Pages (from-to)495-498
Number of pages4
JournalDiabetes Technology and Therapeutics
Volume10
Issue number6
DOIs
Publication statusPublished - Dec 1 2008

Fingerprint

Insulin Aspart
Insulin Lispro
Subcutaneous Infusions
Type 1 Diabetes Mellitus
Glucose
Insulin
Blood Glucose
Lunch
Breakfast
Hypoglycemic Agents
Cross-Over Studies
Area Under Curve
Meals
Carbohydrates

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. / Di Bartolo, Paolo; Pellicano, Francesca; Scaramuzza, Antonio; Sardu, Cipriana; Casetti, Tino; Bosi, Emanuele; Miselli, Valerio; Brandolini, Sara; Fabbri, Tiziano; Meandri, Piero; Cannatà, Francesco.

In: Diabetes Technology and Therapeutics, Vol. 10, No. 6, 01.12.2008, p. 495-498.

Research output: Contribution to journalArticle

Di Bartolo, P, Pellicano, F, Scaramuzza, A, Sardu, C, Casetti, T, Bosi, E, Miselli, V, Brandolini, S, Fabbri, T, Meandri, P & Cannatà, F 2008, 'Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes', Diabetes Technology and Therapeutics, vol. 10, no. 6, pp. 495-498. https://doi.org/10.1089/dia.2008.0013
Di Bartolo, Paolo ; Pellicano, Francesca ; Scaramuzza, Antonio ; Sardu, Cipriana ; Casetti, Tino ; Bosi, Emanuele ; Miselli, Valerio ; Brandolini, Sara ; Fabbri, Tiziano ; Meandri, Piero ; Cannatà, Francesco. / Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. In: Diabetes Technology and Therapeutics. 2008 ; Vol. 10, No. 6. pp. 495-498.
@article{dbdaf5d62cd642488ab9c32742b0b77d,
title = "Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes",
abstract = "Background: Persistent glucose variability is a frequent condition in type 1 diabetes. Continuous subcutaneous insulin infusion (CSII) is a rational option to overcome this clinical issue; however, no comparative studies have been reported for aspart and lispro insulin when used in CSII. This study compare the effects of aspart and lispro delivered by CSII on glycemic stability as measured using a continuous glucose monitoring system. Methods: This single-center, randomized, controlled, 3-day crossover trial included 17 patients with type 1 diabetes. Patients were randomized to receive insulin aspart or insulin lispro. The next day, they received a standard meal at breakfast and lunch and a bolus of insulin aspart or lispro based on insulin:carbohydrate ratio. Patients were monitored for 8 h, after which they received a crossover treatment with insulin aspart or insulin lispro followed by the same procedure as previously. Results: Postprandial blood glucose was more stable with insulin aspart than insulin lispro (absolute Δglucose 7.04 ± 3.16 vs. 9.04 ± 4.2, P <0.0019). Daily blood glucose variability profiles (coefficient of variation and mean amplitude of glucose excursion) and frequency of hypoglycemic episodes (area under the curve",
author = "{Di Bartolo}, Paolo and Francesca Pellicano and Antonio Scaramuzza and Cipriana Sardu and Tino Casetti and Emanuele Bosi and Valerio Miselli and Sara Brandolini and Tiziano Fabbri and Piero Meandri and Francesco Cannat{\`a}",
year = "2008",
month = "12",
day = "1",
doi = "10.1089/dia.2008.0013",
language = "English",
volume = "10",
pages = "495--498",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

AU - Di Bartolo, Paolo

AU - Pellicano, Francesca

AU - Scaramuzza, Antonio

AU - Sardu, Cipriana

AU - Casetti, Tino

AU - Bosi, Emanuele

AU - Miselli, Valerio

AU - Brandolini, Sara

AU - Fabbri, Tiziano

AU - Meandri, Piero

AU - Cannatà, Francesco

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Background: Persistent glucose variability is a frequent condition in type 1 diabetes. Continuous subcutaneous insulin infusion (CSII) is a rational option to overcome this clinical issue; however, no comparative studies have been reported for aspart and lispro insulin when used in CSII. This study compare the effects of aspart and lispro delivered by CSII on glycemic stability as measured using a continuous glucose monitoring system. Methods: This single-center, randomized, controlled, 3-day crossover trial included 17 patients with type 1 diabetes. Patients were randomized to receive insulin aspart or insulin lispro. The next day, they received a standard meal at breakfast and lunch and a bolus of insulin aspart or lispro based on insulin:carbohydrate ratio. Patients were monitored for 8 h, after which they received a crossover treatment with insulin aspart or insulin lispro followed by the same procedure as previously. Results: Postprandial blood glucose was more stable with insulin aspart than insulin lispro (absolute Δglucose 7.04 ± 3.16 vs. 9.04 ± 4.2, P <0.0019). Daily blood glucose variability profiles (coefficient of variation and mean amplitude of glucose excursion) and frequency of hypoglycemic episodes (area under the curve

AB - Background: Persistent glucose variability is a frequent condition in type 1 diabetes. Continuous subcutaneous insulin infusion (CSII) is a rational option to overcome this clinical issue; however, no comparative studies have been reported for aspart and lispro insulin when used in CSII. This study compare the effects of aspart and lispro delivered by CSII on glycemic stability as measured using a continuous glucose monitoring system. Methods: This single-center, randomized, controlled, 3-day crossover trial included 17 patients with type 1 diabetes. Patients were randomized to receive insulin aspart or insulin lispro. The next day, they received a standard meal at breakfast and lunch and a bolus of insulin aspart or lispro based on insulin:carbohydrate ratio. Patients were monitored for 8 h, after which they received a crossover treatment with insulin aspart or insulin lispro followed by the same procedure as previously. Results: Postprandial blood glucose was more stable with insulin aspart than insulin lispro (absolute Δglucose 7.04 ± 3.16 vs. 9.04 ± 4.2, P <0.0019). Daily blood glucose variability profiles (coefficient of variation and mean amplitude of glucose excursion) and frequency of hypoglycemic episodes (area under the curve

UR - http://www.scopus.com/inward/record.url?scp=57349185245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349185245&partnerID=8YFLogxK

U2 - 10.1089/dia.2008.0013

DO - 10.1089/dia.2008.0013

M3 - Article

C2 - 19049379

AN - SCOPUS:57349185245

VL - 10

SP - 495

EP - 498

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 6

ER -